Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 2Gastrointestinal 2Thoracic 1Other 1Genitourinary 1

Conditions

Prostatic Neoplasms 5Motor Activity 3Weight Loss 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Smoking Cessation 1Neoplasms 1Metabolic Syndrome 1Malnutrition 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 28Docetaxel 21Gemcitabine 19Nivolumab 15Paclitaxel 13Prednisone 12Leuprolide 11pazopanib 10Radiotherapy 10Cisplatin 10Sunitinib 9Sorafenib 9Ipilimumab 8Blood Specimen Collection 8Bevacizumab 8avelumab 7atezolizumab 7Therapeutics 7Thalidomide 7Cyclophosphamide 7Carboplatin 7Standard of Care 6Radiation 6Mitomycin 6Interleukin-2 6Cetuximab 6Axitinib 6padeliporfin 5enzalutamide 5cemiplimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Diet × Genitourinary × Clear all
NCT03410641 2018-01-25

Long-term Cancer Risk in the Randomised Oslo Diet and Antismoking Study

Oslo University Hospital

Completed
1,216 enrolled
GastrointestinalGenitourinaryThoracic

Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms, Prostatic Neoplasms, Urologic Neoplasms, Weight Loss, Smoking Cessation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡